Literature DB >> 2532370

A study of the morphology and distribution of amyloid beta protein immunoreactive plaque and related lesions in the brains of Alzheimer's disease and adult Down's syndrome.

S Ikeda1, D Allsop, G G Glenner.   

Abstract

An immunohistochemical study was carried out on the brains of 20 cases with Alzheimer's disease and the same number of non-Alzheimer's controls using a monoclonal antibody to amyloid beta protein. The morphology and distribution of immunoreactive plaque-like lesions and the sensitivity of immunostaining were assessed both with and without formic acid pretreatment of the sections, and these results were compared with those obtained from conventional Congo red and silver impregnation staining methods. The brains of 8 cases with Down's syndrome (ages 18 to 62) were also studied using similar staining techniques. In the cases with Alzheimer's disease Congo red and immunostaining without formic acid pretreatment mainly stained the core deposits of amyloid in compact plaques, whereas the silver stain could also detect numerous diffuse plaques. Immunostaining with formic acid pretreatment was the most sensitive technique, and this showed many additional immunoreactive lesions of faint granular staining with little evidence of amyloid deposition or degenerating neurites. Similar ill-defined, faintly immunoreactive areas were the only neocortical lesions observed in the two cases aged 31 and 38 years respectively, and in addition to these lesions, older cases of Down's syndrome revealed extensive and numerous discrete senile plaques with amyloid deposition. Far fewer immunoreactive lesions were observed in the non-Alzheimer's controls. The ill-defined, beta protein immunoreactive regions mentioned above, therefore, are presumed to be very early stages in senile plaque development, and it is concluded that an extensive appearance of beta protein immunoreactive plaque lesions throughout the cortex and subcortical gray matter structures is typical of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532370

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  4 in total

Review 1.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

2.  Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques.

Authors:  Anna Pensalfini; Ricardo Albay; Suhail Rasool; Jessica W Wu; Asa Hatami; Hiromi Arai; Lawrence Margol; Saskia Milton; Wayne W Poon; Maria M Corrada; Claudia H Kawas; Charles G Glabe
Journal:  Neurobiol Dis       Date:  2014-08-01       Impact factor: 5.996

3.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Authors:  D E Schmechel; A M Saunders; W J Strittmatter; B J Crain; C M Hulette; S H Joo; M A Pericak-Vance; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

4.  Pomegranate polyphenols and extract inhibit nuclear factor of activated T-cell activity and microglial activation in vitro and in a transgenic mouse model of Alzheimer disease.

Authors:  Lalida Rojanathammanee; Kendra L Puig; Colin K Combs
Journal:  J Nutr       Date:  2013-03-06       Impact factor: 4.798

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.